Halozyme Therapeutics (HALO) Competitors $45.76 +0.95 (+2.12%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends HALO vs. MNTA, CBPO, IOVA, TWST, NVAX, BIIB, UTHR, INCY, NBIX, and BMRNShould you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Momenta Pharmaceuticals (MNTA), China Biologic Products (CBPO), Iovance Biotherapeutics (IOVA), Twist Bioscience (TWST), Novavax (NVAX), Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), and BioMarin Pharmaceutical (BMRN). These companies are all part of the "medical" sector. Halozyme Therapeutics vs. Momenta Pharmaceuticals China Biologic Products Iovance Biotherapeutics Twist Bioscience Novavax Biogen United Therapeutics Incyte Neurocrine Biosciences BioMarin Pharmaceutical Momenta Pharmaceuticals (NASDAQ:MNTA) and Halozyme Therapeutics (NASDAQ:HALO) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings. Which has more risk & volatility, MNTA or HALO? Momenta Pharmaceuticals has a beta of 1.71, indicating that its share price is 71% more volatile than the S&P 500. Comparatively, Halozyme Therapeutics has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Does the media prefer MNTA or HALO? In the previous week, Halozyme Therapeutics had 21 more articles in the media than Momenta Pharmaceuticals. MarketBeat recorded 21 mentions for Halozyme Therapeutics and 0 mentions for Momenta Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 0.80 beat Momenta Pharmaceuticals' score of 0.00 indicating that Halozyme Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Momenta Pharmaceuticals Neutral Halozyme Therapeutics Positive Does the MarketBeat Community favor MNTA or HALO? Momenta Pharmaceuticals received 47 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 69.47% of users gave Halozyme Therapeutics an outperform vote while only 66.59% of users gave Momenta Pharmaceuticals an outperform vote. CompanyUnderperformOutperformMomenta PharmaceuticalsOutperform Votes56866.59% Underperform Votes28533.41% Halozyme TherapeuticsOutperform Votes52169.47% Underperform Votes22930.53% Do analysts prefer MNTA or HALO? Halozyme Therapeutics has a consensus target price of $61.11, suggesting a potential upside of 33.55%. Given Halozyme Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Halozyme Therapeutics is more favorable than Momenta Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Momenta Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Halozyme Therapeutics 0 Sell rating(s) 4 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.60 Which has better earnings & valuation, MNTA or HALO? Halozyme Therapeutics has higher revenue and earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMomenta Pharmaceuticals$23.87M261.69-$290.05M-$3.03-17.32Halozyme Therapeutics$829.25M7.02$281.59M$3.0215.15 Is MNTA or HALO more profitable? Halozyme Therapeutics has a net margin of 41.43% compared to Momenta Pharmaceuticals' net margin of -757.61%. Halozyme Therapeutics' return on equity of 179.82% beat Momenta Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Momenta Pharmaceuticals-757.61% -61.44% -45.28% Halozyme Therapeutics 41.43%179.82%23.56% Do institutionals and insiders believe in MNTA or HALO? 97.8% of Halozyme Therapeutics shares are held by institutional investors. 3.4% of Momenta Pharmaceuticals shares are held by company insiders. Comparatively, 2.7% of Halozyme Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. SummaryHalozyme Therapeutics beats Momenta Pharmaceuticals on 14 of the 18 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax Code… And since then… "In the know" patriots have quietly used this same "Trump revenge loophole" to shield their life savings from Bidenomics…Get Your Free Gold Guide Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HALO vs. The Competition Export to ExcelMetricHalozyme TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.82B$2.94B$5.01B$8.81BDividend YieldN/A1.89%5.21%4.07%P/E Ratio15.1543.12126.5217.52Price / Sales7.02359.351,203.9085.12Price / Cash14.37160.0933.3732.51Price / Book72.633.734.684.68Net Income$281.59M-$41.63M$118.36M$225.62M7 Day Performance-21.92%-7.94%-2.46%-2.04%1 Month Performance-13.02%-7.19%-4.06%0.03%1 Year Performance14.37%23.01%29.55%24.47% Halozyme Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HALOHalozyme Therapeutics4.9806 of 5 stars$45.76+2.1%$61.11+33.5%+14.4%$5.70B$829.25M15.15390Analyst ForecastMNTAMomenta PharmaceuticalsN/A$52.48flatN/AN/A$6.25B$23.87M-17.32131CBPOChina Biologic ProductsN/A$119.99+1.7%N/A+0.0%$4.72B$503.70M28.042,269IOVAIovance Biotherapeutics4.0475 of 5 stars$8.14-0.6%$22.33+174.4%+48.3%$2.50B$1.19M0.00500Options VolumeTWSTTwist Bioscience4.1398 of 5 stars$41.11-0.5%$51.78+25.9%+66.2%$2.45B$312.97M0.00990Analyst ForecastAnalyst RevisionNVAXNovavax3.6715 of 5 stars$8.06+0.8%$17.83+121.3%+41.4%$1.28B$983.71M0.001,543Analyst RevisionBIIBBiogen4.8601 of 5 stars$156.00+0.4%$258.96+66.0%-32.2%$22.65B$9.84B14.097,570Analyst DowngradeUTHRUnited Therapeutics4.5219 of 5 stars$364.33+1.0%$370.86+1.8%+59.1%$16.10B$2.33B16.001,168Positive NewsINCYIncyte3.9 of 5 stars$71.05+0.7%$77.16+8.6%+29.9%$13.59B$3.70B507.542,524Analyst ForecastNBIXNeurocrine Biosciences4.9503 of 5 stars$123.29+3.5%$163.91+32.9%+12.7%$12.06B$1.89B33.051,400Positive NewsBMRNBioMarin Pharmaceutical4.9885 of 5 stars$62.56+1.0%$94.20+50.6%-28.5%$11.92B$2.42B37.463,401 Related Companies and Tools Related Companies MNTA Competitors CBPO Competitors IOVA Competitors TWST Competitors NVAX Competitors BIIB Competitors UTHR Competitors INCY Competitors NBIX Competitors BMRN Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:HALO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Halozyme Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Halozyme Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
